Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) - Net Assets
Based on the latest financial reports, Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) has net assets worth CN¥1.46 Billion CNY (≈ $213.42 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.78 Billion ≈ $260.53 Million USD) and total liabilities (CN¥321.96 Million ≈ $47.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Zhejiang Cheng Yi Pharmaceutical Co Ltd for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.46 Billion |
| % of Total Assets | 81.92% |
| Annual Growth Rate | 20.51% |
| 5-Year Change | 39.94% |
| 10-Year Change | 398.92% |
| Growth Volatility | 30.08 |
Zhejiang Cheng Yi Pharmaceutical Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Zhejiang Cheng Yi Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Zhejiang Cheng Yi Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Zhejiang Cheng Yi Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual net assets of Zhejiang Cheng Yi Pharmaceutical Co Ltd from 2011 to 2025. For live valuation and market cap data, see market value of Zhejiang Cheng Yi Pharmaceutical Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.40 Billion ≈ $204.54 Million |
+10.49% |
| 2024-12-31 | CN¥1.27 Billion ≈ $185.12 Million |
+5.72% |
| 2023-12-31 | CN¥1.20 Billion ≈ $175.10 Million |
+9.69% |
| 2022-12-31 | CN¥1.09 Billion ≈ $159.64 Million |
+9.22% |
| 2021-12-31 | CN¥998.88 Million ≈ $146.17 Million |
+12.73% |
| 2020-12-31 | CN¥886.09 Million ≈ $129.66 Million |
+15.23% |
| 2019-12-31 | CN¥768.96 Million ≈ $112.52 Million |
+14.17% |
| 2018-12-31 | CN¥673.54 Million ≈ $98.56 Million |
+12.34% |
| 2017-12-31 | CN¥599.57 Million ≈ $87.74 Million |
+114.01% |
| 2016-12-31 | CN¥280.17 Million ≈ $41.00 Million |
+7.79% |
| 2015-12-31 | CN¥259.92 Million ≈ $38.03 Million |
+5.25% |
| 2014-12-31 | CN¥246.95 Million ≈ $36.14 Million |
+22.62% |
| 2013-12-31 | CN¥201.40 Million ≈ $29.47 Million |
+13.06% |
| 2012-12-31 | CN¥178.13 Million ≈ $26.07 Million |
+73.62% |
| 2011-12-31 | CN¥102.60 Million ≈ $15.01 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Cheng Yi Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12604.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥820.04 Million | 58.98% |
| Other Components | CN¥570.43 Million | 41.02% |
| Total Equity | CN¥1.39 Billion | 100.00% |
Zhejiang Cheng Yi Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Cheng Yi Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wild Bunch AG
F:WBAH
|
$483.64 Million |
|
MN Holdings Berhad
KLSE:0245
|
$483.75 Million |
|
Gallant Precision Machining Co Ltd
TWO:5443
|
$483.80 Million |
|
KKR Credit Income Fund
AU:KKC
|
$483.81 Million |
|
Pangaea Logistic
NASDAQ:PANL
|
$483.40 Million |
|
Jiangsu Rijiu Optoelectronics Joint
SHE:003015
|
$483.26 Million |
|
ACNB Corporation
NASDAQ:ACNB
|
$483.21 Million |
|
VIP Industries Limited
NSE:VIPIND
|
$483.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Cheng Yi Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,260,084,487 to 1,390,465,065, a change of 130,380,578 (10.3%).
- Net income of 195,116,717 contributed positively to equity growth.
- Dividend payments of 83,477,203 reduced retained earnings.
- Other comprehensive income decreased equity by 140,354,228.
- Other factors increased equity by 159,095,293.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥195.12 Million | +14.03% |
| Dividends Paid | CN¥83.48 Million | -6.0% |
| Other Comprehensive Income | CN¥-140.35 Million | -10.09% |
| Other Changes | CN¥159.10 Million | +11.44% |
| Total Change | CN¥- | 10.35% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Cheng Yi Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.35x to 2.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.58 | CN¥7.21 | x |
| 2012-12-31 | CN¥1.01 | CN¥7.21 | x |
| 2013-12-31 | CN¥0.82 | CN¥7.21 | x |
| 2014-12-31 | CN¥1.00 | CN¥7.21 | x |
| 2015-12-31 | CN¥1.06 | CN¥7.21 | x |
| 2016-12-31 | CN¥1.14 | CN¥7.21 | x |
| 2017-12-31 | CN¥1.96 | CN¥7.21 | x |
| 2018-12-31 | CN¥2.01 | CN¥7.21 | x |
| 2019-12-31 | CN¥2.32 | CN¥7.21 | x |
| 2020-12-31 | CN¥2.68 | CN¥7.21 | x |
| 2021-12-31 | CN¥3.01 | CN¥7.21 | x |
| 2022-12-31 | CN¥3.30 | CN¥7.21 | x |
| 2023-12-31 | CN¥3.66 | CN¥7.21 | x |
| 2024-12-31 | CN¥3.83 | CN¥7.21 | x |
| 2025-12-31 | CN¥3.03 | CN¥7.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Cheng Yi Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.03%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.02%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.22x
- Recent ROE (14.03%) is below the historical average (16.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 13.01% | 6.20% | 0.73x | 2.88x | CN¥3.09 Million |
| 2012 | 16.45% | 11.47% | 0.71x | 2.01x | CN¥11.49 Million |
| 2013 | 18.12% | 13.72% | 0.80x | 1.66x | CN¥16.36 Million |
| 2014 | 21.81% | 16.82% | 0.97x | 1.34x | CN¥29.16 Million |
| 2015 | 22.20% | 18.21% | 0.92x | 1.33x | CN¥31.71 Million |
| 2016 | 24.33% | 21.22% | 0.88x | 1.30x | CN¥40.15 Million |
| 2017 | 11.55% | 20.31% | 0.51x | 1.12x | CN¥9.28 Million |
| 2018 | 14.67% | 17.76% | 0.67x | 1.23x | CN¥30.83 Million |
| 2019 | 17.37% | 19.29% | 0.69x | 1.30x | CN¥55.73 Million |
| 2020 | 18.90% | 21.78% | 0.63x | 1.38x | CN¥77.75 Million |
| 2021 | 17.32% | 24.61% | 0.52x | 1.34x | CN¥72.17 Million |
| 2022 | 14.85% | 24.67% | 0.38x | 1.58x | CN¥52.79 Million |
| 2023 | 13.66% | 24.25% | 0.35x | 1.59x | CN¥43.67 Million |
| 2024 | 15.93% | 28.09% | 0.41x | 1.37x | CN¥74.69 Million |
| 2025 | 14.03% | 24.02% | 0.48x | 1.22x | CN¥56.07 Million |
Industry Comparison
This section compares Zhejiang Cheng Yi Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,133,881,544
- Average return on equity (ROE) among peers: 2.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) | CN¥1.46 Billion | 13.01% | 0.22x | $483.45 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $868.76 Million | 4.89% | 3.05x | $639.13 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $775.01 Million | 2.45% | 0.87x | $378.07 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $5.07 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $662.32 Million | 12.10% | 0.68x | $2.59 Billion |
| Wedge Industrial Co Ltd (000534) | $692.08 Million | 2.78% | 1.05x | $1.97 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $13.23 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.49 Billion | 5.19% | 0.85x | $1.11 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $302.41 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.75 Billion | 0.46% | 2.42x | $956.43 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.16 Billion |
About Zhejiang Cheng Yi Pharmaceutical Co Ltd
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of formulations and active pharmaceutical ingredients in China and internationally. The company offers glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, ribavirin preparations raw materials, and sulfur dioxide raw materials. It also provides injections, food, cap… Read more